AstraZeneca Pharma India plans to sell Bengaluru plant

Share via:

AstraZeneca Pharma India announced that it plans to sell its manufacturing site in Bengaluru is part of a strategic review of its global manufacturing and supply network.

The company aims to continue being a pioneer in the pharmaceutical industry by leading in specialized disease areas and transforming patient outcomes.

The company’s to India

Despite the impending sale, AstraZeneca said it remains dedicated to advancing access to innovative medicines within India. The company asserted that its goal to lead in science and cater to specialist disease areas remains steadfast. They are fully aware of the implications of this change and have pledged to prioritize their employees and patients, ensuring that the supply of medicines remains uninterrupted.

“AstraZeneca Pharma India Limited (Company) remains committed to advance access to innovative medicines in India, with a clear ambition to be pioneers in science, lead in specialist disease areas, and transform patient outcomes. As a part of AstraZeneca’s ongoing strategic review of its Global Manufacturing and Supply Network, the Company intends to exit the manufacturing site in Bangalore, in due course,” the company informed in an exchange filing on November 16.

Operational sale

The company is preparing to position the Bengaluru manufacturing facility as fully operational for sale. It is also initiating the search for a buyer who can also serve as a Contract Manufacturing Organisation (CMO) for the products currently manufactured or packaged at the site.

The process will be conducted in compliance with all necessary statutory approvals, the company added.

What does AstraZeneca do?

Established in 1979 with its headquarters in Bengaluru, AstraZeneca Pharma India is a subsidiary of the UK-based AstraZeneca Plc. The Indian arm, which is listed and operates independently, employs over 1,400 individuals.

It has been focusing on the discovery, development, and commercialization of prescription medicines, especially in the therapy areas of oncology, cardiovascular, renal and metabolism, and respiratory diseases.

Join our new WhatsApp Channel for the latest startup news updates

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Popular

More Like this

AstraZeneca Pharma India plans to sell Bengaluru plant

AstraZeneca Pharma India announced that it plans to sell its manufacturing site in Bengaluru is part of a strategic review of its global manufacturing and supply network.

The company aims to continue being a pioneer in the pharmaceutical industry by leading in specialized disease areas and transforming patient outcomes.

The company’s to India

Despite the impending sale, AstraZeneca said it remains dedicated to advancing access to innovative medicines within India. The company asserted that its goal to lead in science and cater to specialist disease areas remains steadfast. They are fully aware of the implications of this change and have pledged to prioritize their employees and patients, ensuring that the supply of medicines remains uninterrupted.

“AstraZeneca Pharma India Limited (Company) remains committed to advance access to innovative medicines in India, with a clear ambition to be pioneers in science, lead in specialist disease areas, and transform patient outcomes. As a part of AstraZeneca’s ongoing strategic review of its Global Manufacturing and Supply Network, the Company intends to exit the manufacturing site in Bangalore, in due course,” the company informed in an exchange filing on November 16.

Operational sale

The company is preparing to position the Bengaluru manufacturing facility as fully operational for sale. It is also initiating the search for a buyer who can also serve as a Contract Manufacturing Organisation (CMO) for the products currently manufactured or packaged at the site.

The process will be conducted in compliance with all necessary statutory approvals, the company added.

What does AstraZeneca do?

Established in 1979 with its headquarters in Bengaluru, AstraZeneca Pharma India is a subsidiary of the UK-based AstraZeneca Plc. The Indian arm, which is listed and operates independently, employs over 1,400 individuals.

It has been focusing on the discovery, development, and commercialization of prescription medicines, especially in the therapy areas of oncology, cardiovascular, renal and metabolism, and respiratory diseases.

Join our new WhatsApp Channel for the latest startup news updates

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

More like this

Swift, UBS, Chainlink pilot tokenized fund settlement

Swift, UBS and Chainlink aim to modernize traditional...

PayPay expands digital wage payment system in Japan

PayPay's digital wage payment service was initially exclusive...

Apple @ Work Podcast: Password security 101

Apple @ Work is exclusively brought to you...

Popular

Upcoming Events

Startup Information that matters. Get in your inbox Daily!